Pharmaceuticals

IMPACT THERAP-B

7630.HK released FY2025 Annual Earnings on May 5, 2026 (BJT), with actual revenue of HKD 41.81 M and EPS of HKD -1.415

IMPACT THERAP-B released FY2024 annual earnings on May 5, 2026 (BJT), actual revenue HKD 36.31 M, actual EPS HKD -1.3752

JOLIMARK

PANGAEA CONNECT

WEILI HOLDINGS

MAN YUE TECH

SMIT

BJ DIGITAL

FY FINANCIAL

NEW GONOW RV

RADIANCE HLDGS

PERFECTECH INTL

06651

02513

02431

07630

00992

02643

02476

03277

00100

03396

51WORLD(06651) rose 28.57%, with a trading turnover 2.2 Billion HKD, and a year-to-date rose 140.4%. KNOWLEDGE ATLAS(02513) rose 26.93%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 1003.3%. MINIEYE(02431) rose 23.64%, with a trading turnover 669.7 Million HKD, and a year-to-date fell 27.5%.

Top Gainers&Losers

51WORLD

KNOWLEDGE ATLAS

MINIEYE

LENOVO GROUP

CAOCAO INC

GPIXEL

MINIMAX-W

LEGENDHOLDING

Top 10 HK Stock Gainers (5.22)

IMPACT THERAP-B rose 16.16%; CSPC Pharmaceutical Group rose 4.50%, with a transaction volume of HKD 686 million; Heng Rui Medicine fell 1.68%, with a transaction volume of HKD 186 million; China National Pharmaceutical Group fell 1.14%, with a transaction volume of HKD 174 million; Hansoh Pharmaceutical fell 1.41%, with a market value of HKD 203.9 billion

HK Stock Alerts

CSPC PHARMA

HENGRUI PHARMA

SBP GROUP

HANSOH PHARMA

Hong Kong Stock Movement: IMPACT THERAP-B rebounds 16.16%, can the market sentiment recovery be sustained? The volatility of newly listed stocks raises concerns

IMPACT THERAP-B rose 13.74%; CSPC Pharmaceutical Group rose 4.77%, with a transaction volume of HKD 661 million; China Biologic Products fell 0.76%, with a transaction volume of HKD 162 million; Heng Rui Medicine fell 1.36%, with a transaction volume of HKD 156 million; Hansoh Pharmaceutical fell 1.23%, with a market value of HKD 204.2 billion

Hong Kong Stock Movement: IMPACT THERAP-B rebounds by 13.74%, can the market sentiment recovery be sustained? Risks of newly listed stocks still need to be vigilant

02477

02940

06871

09993

01879

02565

01384

02218

07688

WELLCELL HOLD(02477) fell 83.16%, with a trading turnover 4.6 Billion HKD, and a year-to-date fell 75.2%. WELLCELL HOLD(02940) fell 83.1%, with a trading turnover 331.8 Million HKD, and a year-to-date fell 74.9%. ROBOTPHOENIX(06871) fell 23.21%, with a trading turnover 108.8 Million HKD, and a year-to-date rose 3.3%.

WELLCELL HOLD

ROBOTPHOENIX

XIZHI TECH-P

PEGBIO CO-B

DEEPEXI TECH

ANDRE JUICE

TOPNC

Top 10 HK Stock Losers (5.21)

Impact Therapeutics, a biotech firm specializing in synthetic lethality drugs, made a strong debut on the Hong Kong stock market, with shares doubling on the first day. The company raised approximately HK$844 million ($108 million) through its IPO, which was oversubscribed by over 2000 times. Its core product, senaparib, is a PARP inhibitor approved in China for advanced ovarian cancer. Despite significant R&D losses, the company aims to use IPO proceeds to further develop senaparib and other pipeline drugs, targeting a growing market for precision cancer therapies.

benzinga_article

Goldman Sachs

CICC

HUADONG MEDICINE

AstraZeneca

AstraZeneca PLC

Hengrui Pharma

TENCENT

Tencent

JUNSHI BIO

Junshi Biosciences

WUXI APPTEC

WuXi AppTec

GS Hldg R

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Precision-Drug maker Impact Therapeutics Ignites IPO Frenzy

IMPACT THERAP-B was listed on the Hong Kong stock market, becoming the first innovative oncology drug company based on the "synthetic lethality" mechanism. On its first day of trading, the stock price surged by 108.26%, closing at HKD 41.86. This IPO globally offered approximately 41.98 million shares, raising a net amount of HKD 759 million, with the public offering portion oversubscribed by more than 2,281 times. Although the company is still in a state of significant losses, with a projected net loss of HKD 296 million in 2025, its core product, Senaparib, has been approved and included in the medical insurance catalog, becoming the focus of market attention

BambooWorks

WUXI BIO

WuXi Biologics

Hong Kong stocks "synthetic death" first stock IMPACT THERAP-B first listing stock price doubled

IMPACT THERAP-Bclosed at $32.16 on gray market yesterday, up 60.0% from the listing price of $20.1. On debut today, the stock opened at $35.5, up 76.6% from the listing price of $20.1, 7.93 million shares traded at market open.(HK stocks quote is delayed for at least 15 mins.)

AASTOCKS News

IMPACT THERAP-B Opens Up 76.6% to $35.5 on Debut

IMPACT THERAP-B(07630.HK)